Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET To register for the In Person Event or Live Webcast, click here: https://ow.ly/YbQQ50TBTjo
Valneva
Recherche en biotechnologie
Saint-Herblain, Pays de la Loire 37 972 abonnés
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
À propos
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
- Site web
-
http://www.valneva.com
Lien externe pour Valneva
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 501-1 000 employés
- Siège social
- Saint-Herblain, Pays de la Loire
- Type
- Société cotée en bourse
- Fondée en
- 2013
- Domaines
- vaccines
Lieux
Employés chez Valneva
Nouvelles
-
Today is #WorldTourismDay! At Valneva, we are committed to empowering adventures. Traveling not only provides us with a way to explore new destinations and cultures, but it can also bring us closer to our loved ones. As we celebrate the spirit of exploration today, we asked some of our Valneva team members about their greatest adventures, and what traveling means to them. We continue to prioritize the development of new vaccines for vector-borne diseases to help keep those traveling internationally safe. To learn more about our commitment to travel health and empowering adventures, visit: https://rb.gy/4ujbpj #Travel #Vaccines #Health #Adventure #AdvancingVaccinesForBetterLives
-
Curious about how innovative pull funding can boost R&D to address unmet medical needs worldwide? Don’t miss the opportunity to hear from representatives of the Drugs for Neglected Diseases initiative - DNDi, Geneva Graduate Institute Global Health Centre, Deutsche Stiftung Weltbevoelkerung (DSW), and Valneva at the European Health Forum Gastein, Austria, this Wednesday. https://lnkd.in/dWTQvXsb #EHFG2024 #Chikungunya #vaccines #globalhealth
Despite the European Union’s leadership in science, there is a gap in translating excellent research into final products. Whilst push funding helps subsidise the start up costs of research, pull funding can help research go from findings to health impact. Both push and pull are crucial to fulfil the unmet health needs of many patients around the world. 🌍 Want to learn how innovative pull funding mechanisms could stimulate R&D for neglected diseases? Join representatives from Drugs for Neglected Diseases initiative - DNDi, Valneva, the Geneva Graduate Institute Global Health Centre, and Deutsche Stiftung Weltbevoelkerung (DSW) at #EHFG2024 as they share valuable insights. 📅 25 September ⏰ 09:00 - 10:00 CEST 📲 https://bit.ly/3Lm7L0u #GlobalHealth #BeatNTDs
-
Scotland's largest vaccine manufacturer, Valneva Scotland, marked World Patient Safety Day and pledged its support to continue efforts to improve patient safety globally. It helped "cast an orange glow across the globe” by lighting its Manson manufacturing building to highlight the importance of correct and timely diagnosis for patient safety.
-
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada https://ow.ly/Pvii50TpJSu
-
This World Patient Safety Day, we at Valneva proudly support the World Health Organization as they elevate the voice of patients worldwide. Today, the understanding that infectious diseases represent an immense public health threat is widespread and undeniable. At Valneva, we continue to prioritize development of safe and effective solutions, to ultimately benefit the health and wellbeing of patients worldwide by mitigating easily preventable deaths through vaccinations. We hope to encourage collaboration among governments and healthcare leaders to champion patient safety and work towards a future where everyone has equitable access to the protection they need. #WorldPatientSafetyDay #PatientSafety #Healthcare #AdvancingVaccinesForBetterLives
-
Valneva Announces the Success of its Private Placement Raising approximately €60 Million https://ow.ly/ZJXo50TmACg
-
What a run! Although it has already become a true tradition for Valneva, running the Vienna Business Run is exciting every year. 41 motivated Austrian colleagues🏃 joined 33.000 other runners in the 4.3 km run on the beautiful Danube Island last Friday. We were overwhelmed by the team spirit and the ambition of our runners. We congratulate them all and thank the organizers for making this event run so smoothly. See you again next year! #AdvancingVaccinesForBetterLives
-
We are continuing with our #EmployeeSpotlight series – meet Jana! Jana is one of our Clinical Operations Managers here at Valneva. Her role is to collect clinical data that show the efficacy and safety of our vaccines, to support with registration of our products with the authorities. Thanks to our expert team members like Jana, we continue to successfully advance a broad range of vaccine candidates, supporting our bold mission to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Check out our interview with Jana to learn more about her role and why she enjoys working at Valneva. #AdvancingVaccinesForBetterLives
-
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate https://ow.ly/ZPBr50TcUug
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse67 833 293,00 $US